Subjects in study group must have banked AdMSCs at Celltex (already passed communicable disease screen tests for HIV, syphilis and Hepatitis B and C during banking stage)
Must understand and voluntarily sign an Informed Consent for study participation obtained prior to undergoing any study-specific procedures
Must be diagnosed as OA-knees, OA-hips, or OA-shoulders by radiographic criteria and physical examination.
You may not be if
Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start
Unwillingness or inability to comply with study procedures
Patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc.
Clinically active malignant disease
Previous thrombotic disorder
History of known pulmonary embolism or known secondary anti-phospholipid syndrome
Known or suspected hypersensitivity to any components used to culture the AdMSCs, e.g. BSA and sulfur-containing products (e.g., DMSO)
Major trauma or surgery within 14 days of study treatment start
Mental condition rendering the subject (or the subject's legally acceptable representative\[s\]) unable to understand the nature, scope and possible consequences of the study
Alcohol, drug, or medication abuse within one year prior to study treatment start
Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study
Irreversible severe end-organ failure, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions
Patients or family history with a hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.
History of long-term use of immunosuppressive agents
Organ transplants in the previous 6 months
Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study
Clareo Health | Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
